Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Morgan Stanley Initiates Coverage On Integra Lifesciences with Equal-Weight Rating, Announces Price Target of $59

Morgan Stanley analyst Drew Ranieri initiates coverage on Integra Lifesciences (NASDAQ:IART) with a Equal-Weight rating and announces Price Target of $59.
byBenzinga Newsdesk
July 25, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Morgan Stanley analyst Drew Ranieri initiates coverage on Integra Lifesciences (NASDAQ:IART) with a Equal-Weight rating and announces Price Target of $59.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Culp Announces Broad Restructuring Plan Primarily Focused On Mattress Fabrics Segment Reduce The Number Of Associates By ~240 People, Representing Around 35% Of The Segment’s Total Workforce, Expected To Generate $10M-$11M In Annualized Cost Savings

By Benzinga Newsdesk
May 1, 5:23 PM
Expect to achieve $10.0 - $11.0 million in annualized savings and operating improvements with restructuring initiativesExpect a return to break even operating results at current industry demand levels post

CULP